A study details the potential of a GCN2 modulator to overcome drug resistance, a major clinical challenge, based on preclinical efficacy of HC-7366, a GCN2 activator, in AML models, which induces significant anti-tumor effects both as a standalone therapy and in combination with the standard-of-care drug (Tameire et al., 2023). Here, EIF2AK4 is linked to acute myeloid leukemia.